Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Deutsche Bank AG (DB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Deutsche Bank AG — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.03B), while Deutsche Bank AG trades at $38.21 (market cap $72.15B). The key difference: Deutsche Bank AG is far larger — about 2.5× Alnylam Pharmaceuticals, Inc.'s market cap, and Deutsche Bank AG pays a 3.04% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | DB | |
|---|---|---|
Market Cap | $29.03B | $72.15B |
Sector | Health | Financials |
52-Week High | $491.22 | $40.33 |
52-Week Low | $205.48 | $28.37 |
Enterprise Value | $26.99B | — |
Dividend Yield | — | 3.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $219.20, down 1.43% amid bearish technical signals and recent earnings volatility. The stock faces near-term pressure from a Q2 2026 EPS miss and lowered 2026 sales guidance, but maintains strong fundamentals with 2025 revenue of $3.71B and net income of $313.75M. Analyst consensus remains bullish with a $370.07 price target, though multiple law firms are investigating potential securities fraud as reported by PRNewsWire and GlobeNewsWire in early August 2026.
Outlook is mixed: robust revenue growth and high profitability margins support long-term potential, but legal uncertainties and recent earnings disappointments pose significant risks. The stock's current valuation (P/E 38.19) reflects growth expectations, yet investor caution is warranted given technical bearishness and ongoing investigations.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →
